Evidence map›Paper›PMID 40775250›Full record

ArticleScientific reports2025

Sorafenib-treated Th9 cells exhibit superior anti-tumor effect in lung metastasis.

Fanli Yuan, Hanliang Wang, Shuowang Wang, Jin Wang, Junwei Li, Yingying Shen, Jianjun Lin, Jufeng Guo, Lingzhi Cai

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Fanli Yuan *Clinical Laboratory, Affiliated Xiangshan Hospital of Wenzhou Medical University, Ningbo, 315700, Zhejiang, China.
Hanliang Wang *Department of Breast Surgery, Affiliated Hangzhou First People's Hospital, School of Medicine, Westlake University, Hangzhou, 310006, Zhejiang, China.
Shuowang Wang *Department of Medical Oncology, Cancer Center of Zhejiang University, Sir Run Run Shaw Hospital, Medical School of Zhejiang University, Hangzhou, 310020, Zhejiang, China.
Jin WangDepartment of Medical Oncology, Cancer Center of Zhejiang University, Sir Run Run Shaw Hospital, Medical School of Zhejiang University, Hangzhou, 310020, Zhejiang, China.
Junwei LiDepartment of Medical Oncology, Cancer Center of Zhejiang University, Sir Run Run Shaw Hospital, Medical School of Zhejiang University, Hangzhou, 310020, Zhejiang, China.
Yingying ShenDepartment of Medical Oncology, Cancer Center of Zhejiang University, Sir Run Run Shaw Hospital, Medical School of Zhejiang University, Hangzhou, 310020, Zhejiang, China.
Jianjun LinClinical Laboratory, Affiliated Xiangshan Hospital of Wenzhou Medical University, Ningbo, 315700, Zhejiang, China.
Jufeng GuoDepartment of Breast Surgery, Affiliated Hangzhou First People's Hospital, School of Medicine, Westlake University, Hangzhou, 310006, Zhejiang, China. 21118181@zju.edu.cn.
Lingzhi CaiDepartment of Breast Surgery, Affiliated Hangzhou First People's Hospital, School of Medicine, Westlake University, Hangzhou, 310006, Zhejiang, China. m18758114522@163.com.

Funding

the Department of Healthcare in Zhejiang Province 2022481544/2022RC222the National Natural Science Foundation of China 82371751
6 · The paper itself

Abstract

The lung is the second most common organ of tumor metastasis, with limited treatment options and disappointing treatment outcomes. T helper 9 (Th9) cells have been reported to be effective in the elimination of solid tumors and exhibit superior antitumor properties to T helper 1 (Th1) and T helper 17 (Th17) cells, which makes a potential candidate for Adoptive cell therapy (ACT) against lung metastasis. However, how Th9 cells can be massively expanded in vitro is not clear. Here, we found Sorafenib (Sora) can increase the efficiency of Th9 in vitro through ERK signaling. In addition, Sora-treated Th9 cells exhibit superior anti-tumor effects by reshaping tumor immune microenvironment in lung metastasis mice model. Thus, our findings provide a potential method to expand Th9 cells in vitro for lung metastasis treatment.

Indexed as

Antineoplastic AgentsLung NeoplasmsSorafenibT-Lymphocytes, Helper-InducerAnimalsCell Line, TumorHumansMAP Kinase Signaling SystemMiceTumor MicroenvironmentAntineoplastic AgentsSorafenibERKLung metastasisSorafenibTh9 cellTumor immunity

Identifiers

PMID40775250
PMCPMC12331935

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.